Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Metastatic Gastric/Gastroesophageal Junction Cancer in Commercially Insured Patients in the United States
Author(s)
Ziyan Chen, PhD1, Jenna Abdelhadi, MS2, Jennifer Wang, PhD2, Akeem Yusuf, PhD2, Istvan MAJER, PhD3.
1Amgen Inc., Tampa, FL, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen (Europe) GmbH, Rotkreuz, Switzerland.
1Amgen Inc., Tampa, FL, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Presentation Documents
OBJECTIVES: This study describes real-world patient characteristics, recent treatment patterns, healthcare resource utilization (HCRU), and costs among commercially insured patients with metastatic G/GEJC during first-line (1L) therapy.
METHODS: A retrospective observational cohort study was conducted using Merative™ MarketScan® Commercial and Medicare Databases. Patients (age ≥18 years) diagnosed with metastatic G/GEJC who initiated non-HER2-targeted 1L systemic anticancer therapy between 16 April 2021 and 31 March 2024, continuously insured for at least 6 months before and 1 month after the initiation of the 1L therapy (index date) were identified. Outcomes were assessed during the follow-up period from the index date to the end of continuous enrollment or study end date (30 June 2024), whichever occurred first. All analyses were descriptive.
RESULTS: A total of 328 patients received 1L G/GEJC treatment. At treatment initiation, the mean age was 58 years, with 78% of patients being ≥65 years old and 72% male. The most frequent comorbidities were mild liver disease (24%) and peptic ulcer disease (20%). The mean time from the first metastatic G/GEJC diagnosis to the initiation of 1L therapy was 30 days. The 3 most frequently used regimens were nivolumab plus FOLFOX (36.9%), followed by FOLFOX (28.0%), and carboplatin plus paclitaxel (8.5%). Mean treatment duration was 4.1 months. Outpatient visits represented the majority of HCRU (7.5 per patient per month [PPPM]). The average total all-cause healthcare cost was $35,620 PPPM, with outpatient costs accounting for more than half of the total costs ($24,329 PPPM).
CONCLUSIONS: Based on recent treatment patterns data of commercially insured patients in the US, this analysis suggests that most patients receive standard chemotherapy for 1L metastatic G/GEJC. Despite increased treatment options, the 1L treatment of metastatic G/GEJC remains associated with short treatment duration and high economic burden, suggesting significant remaining unmet need.
METHODS: A retrospective observational cohort study was conducted using Merative™ MarketScan® Commercial and Medicare Databases. Patients (age ≥18 years) diagnosed with metastatic G/GEJC who initiated non-HER2-targeted 1L systemic anticancer therapy between 16 April 2021 and 31 March 2024, continuously insured for at least 6 months before and 1 month after the initiation of the 1L therapy (index date) were identified. Outcomes were assessed during the follow-up period from the index date to the end of continuous enrollment or study end date (30 June 2024), whichever occurred first. All analyses were descriptive.
RESULTS: A total of 328 patients received 1L G/GEJC treatment. At treatment initiation, the mean age was 58 years, with 78% of patients being ≥65 years old and 72% male. The most frequent comorbidities were mild liver disease (24%) and peptic ulcer disease (20%). The mean time from the first metastatic G/GEJC diagnosis to the initiation of 1L therapy was 30 days. The 3 most frequently used regimens were nivolumab plus FOLFOX (36.9%), followed by FOLFOX (28.0%), and carboplatin plus paclitaxel (8.5%). Mean treatment duration was 4.1 months. Outpatient visits represented the majority of HCRU (7.5 per patient per month [PPPM]). The average total all-cause healthcare cost was $35,620 PPPM, with outpatient costs accounting for more than half of the total costs ($24,329 PPPM).
CONCLUSIONS: Based on recent treatment patterns data of commercially insured patients in the US, this analysis suggests that most patients receive standard chemotherapy for 1L metastatic G/GEJC. Despite increased treatment options, the 1L treatment of metastatic G/GEJC remains associated with short treatment duration and high economic burden, suggesting significant remaining unmet need.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE528
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology